Antares Pharma Inc. (NASDAQ:ATRS) withdrew - 1.97% and shut its last session at $1.99. The stock has the market capitalization of $308.65 Million with the aggregate remarkable shares of 155.1 Million. Antares Pharma Inc.. has Analysts' Mean Recommendation of 1 between the size of 1 to 5 (1 speaks to Strong Buy and 5 implies Sell). The stock at present has P/E of 0 for trailing twelve months while its Forward P/E is 0.
Antares Pharma Inc. (NASDAQ:ATRS) touched its 52-Week High of $2.09 on Nov 28, 2016 while it's 52-Week Low of $0.67 on Mar 18, 2016. The organization as of now has Return on Assets of - 33.4 percent, Return on Equity of - 45.9% and Return on Investment of - 30.8 percent. The stock right now indicating Weekly Volatility of 5.85%% and Monthly Volatility of 7.10% Percent and Beta of 0.95.
The 3 investigators offering 12-month value gauges for Antares Pharma Inc have a middle focus of 3.00, with a high gauge of 3.00 and a low gauge of 2.00. The middle gauge speaks to a +50.75% expansion from the last cost of 1.99.
Official statement:
The Company on 23 November proclaimed that Robert F. Apple, President and Chief Executive Officer, will display at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday November 30, 2016 at 3:30 pm, Eastern Time.
Organization Profile:
Antares Pharma, Inc. creates, popularizes and showcases novel conveyance arrangements, including sans needle and smaller than normal needle injector frameworks, gel advances and transdermal items, which enhance both the productivity of medication treatments and the personal satisfaction for patients. The Company at present conveys its sans needle injector frameworks for the conveyance of insulin and development hormone in more than 20 nations and an estradiol transdermal fix for hormone substitution treatment.
Antares Pharma Inc. (NASDAQ:ATRS) touched its 52-Week High of $2.09 on Nov 28, 2016 while it's 52-Week Low of $0.67 on Mar 18, 2016. The organization as of now has Return on Assets of - 33.4 percent, Return on Equity of - 45.9% and Return on Investment of - 30.8 percent. The stock right now indicating Weekly Volatility of 5.85%% and Monthly Volatility of 7.10% Percent and Beta of 0.95.
The 3 investigators offering 12-month value gauges for Antares Pharma Inc have a middle focus of 3.00, with a high gauge of 3.00 and a low gauge of 2.00. The middle gauge speaks to a +50.75% expansion from the last cost of 1.99.
Official statement:
The Company on 23 November proclaimed that Robert F. Apple, President and Chief Executive Officer, will display at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday November 30, 2016 at 3:30 pm, Eastern Time.
Organization Profile:
Antares Pharma, Inc. creates, popularizes and showcases novel conveyance arrangements, including sans needle and smaller than normal needle injector frameworks, gel advances and transdermal items, which enhance both the productivity of medication treatments and the personal satisfaction for patients. The Company at present conveys its sans needle injector frameworks for the conveyance of insulin and development hormone in more than 20 nations and an estradiol transdermal fix for hormone substitution treatment.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.